CDK5 and prostate carcinoma: Regulation of CDK5 depends on its activator p35, the expression of which increases in aging cells and tumor cells (osteosarcoma, prostate cancer, colorectal cancer) and is required for the activation of CDK5 induced by pRB during the unfolding of the senescence program.